US 12,377,082 B2
Nicorandil derivatives
Shalabh Gupta, Mountain View, CA (US); and Sundeep Dugar, San Jose, CA (US)
Assigned to UNICYCIVE THERAPEUTICS INC., Los Altos, CA (US)
Appl. No. 17/439,781
Filed by UNICYCIVE THERAPEUTICS INC., Los Altos, CA (US)
PCT Filed Mar. 16, 2020, PCT No. PCT/US2020/023016
§ 371(c)(1), (2) Date Sep. 15, 2021,
PCT Pub. No. WO2020/190890, PCT Pub. Date Sep. 24, 2020.
Claims priority of provisional application 62/819,372, filed on Mar. 15, 2019.
Prior Publication US 2022/0265630 A1, Aug. 25, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4425 (2006.01); A61K 31/4545 (2006.01); A61K 31/455 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/4425 (2013.01) [A61K 31/4545 (2013.01); A61K 31/455 (2013.01); A61P 13/12 (2018.01)] 14 Claims
 
1. A method for treating a disease or a condition related to kidney in a mammal, wherein the method comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound according to formula (Va) or formula (Vb):

OG Complex Work Unit Chemistry
or a pharmaceutical composition thereof;
wherein X− is a counter ion, and
wherein the disease or condition related to kidney is chronic kidney disease.